Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Axsome Therapeutics (AXSM) Leases (2021 - 2026)

Axsome Therapeutics' Leases history spans 6 years, with the latest figure at $20.0 million for Q1 2026.

  • On a quarterly basis, Leases fell 16.26% to $20.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $20.0 million, a 16.26% decrease, with the full-year FY2025 number at $20.9 million, up 287.48% from a year prior.
  • Leases hit $20.0 million in Q1 2026 for Axsome Therapeutics, down from $20.9 million in the prior quarter.
  • Over the last five years, Leases for AXSM hit a ceiling of $23.9 million in Q1 2025 and a floor of $106000.0 in Q1 2023.
  • Historically, Leases has averaged $9.2 million across 5 years, with a median of $6.4 million in 2024.
  • Biggest five-year swings in Leases: plummeted 88.8% in 2023 and later soared 5948.11% in 2024.
  • Tracing AXSM's Leases over 5 years: stood at $420000.0 in 2022, then skyrocketed by 1512.38% to $6.8 million in 2023, then decreased by 20.51% to $5.4 million in 2024, then skyrocketed by 287.48% to $20.9 million in 2025, then fell by 4.05% to $20.0 million in 2026.
  • Business Quant data shows Leases for AXSM at $20.0 million in Q1 2026, $20.9 million in Q4 2025, and $21.7 million in Q3 2025.